Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06435468
Other study ID # 69HCL23_1252
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 2024
Est. completion date July 2034

Study information

Verified date May 2024
Source Hospices Civils de Lyon
Contact BELOT Alexandre, Pr
Phone + 33 4 27 85 61 26
Email Alexandre.belot@chu-lyon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rare diseases are defined as those that affect one person in 2,000, or around three million people in France. The majority of rare diseases are caused by genetics and tend to be severe when they begin in childhood. Autoimmune and autoinflammatory diseases, such as systemic lupus, juvenile dermatomyositis, and juvenile idiopathic arthritis, are examples of rare pediatric diseases. While autoimmune diseases are characterized by an inappropriate adaptive immune response, autoinflammatory diseases involve an excess of the innate immune response. The precise mechanisms of these diseases are not yet fully understood, but recent research has led to advances in their diagnosis and identification, particularly in early onset and familial forms. However, the rarity of these diseases and limited availability of biological samples pose significant challenges. This study aims to create a biological collection, which includes primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, that will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases through various research projects.


Description:

A disease is said to be "rare" when it affects one person in 2,000, which represents three million people in France. Most rare diseases (80%) are genetic in origin ; the earlier they start in childhood, the more severe they can be. Rare pediatric diseases include autoimmune diseases (systemic lupus, juvenile dermatomyositis and juvenile idiopathic arthritis) and autoimmune diseases (interferonopathies, FMF, CAPS, TRAPS, and DADA2). Systemic autoimmune diseases are characterized by an inappropriate adaptive immune response (mediated by autoreactive T and/or B lymphocytes) with the production of autoantibodies directed against the constituents of the self (tolerance breakdown). Autoinflammatory diseases, unlike autoimmune diseases, correspond to an excess in the innate immune response (cytokines, macrophages, NK cells, granulocytes, etc.)..The precise pathophysiological mechanisms of these diseases have yet to be fully elucidated. Recent research has led to advances in the diagnosis and identification of monogenic forms of these diseases, particularly in early onset, familial, and syndromic forms. Nevertheless, the rarity of these diseases and limited availability of biological samples are major challenges that need to be overcome. Thus, the aims of this study were as follows: - The creation of a biological collection: primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, which, through various research projects, will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 400
Est. completion date July 2034
Est. primary completion date July 2034
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Year and older
Eligibility Inclusion Criteria: - Patients - minor or adult patient of any age with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years), or syndromic or familial - relative of a minor or adult patient with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years of age) or syndromic or familial, - weight greater than 5 kg - Patient/parents/guardians who were informed of the study and signed the consent form. - patient affiliated to a social security scheme Healthy volunteer participants - minor or adult participants with no age restrictions - weight over 5 kg - Subject /Parents/guardians who were informed of the study and signed a consent form. - Patient affiliated to a social security scheme Exclusion Criteria: Patients - Subjects /Parents/guardians, refusing to participate in the study Healthy volunteer participants : - active infection (viral, bacterial, parasitic) - history of neoplasia (< 5 years) or current neoplasia - participants with a personal or family history of autoimmune disease - immunocompromised participant (immune deficiency or transplant recipient) - Subjects/parents/guardians refusing to participate in the study - Adults under legal protection (guardianship, curatorship)

Study Design


Intervention

Genetic:
Blood sample for genetic analysis
genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood
Other:
Blood sample for immunological response assessments
Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases
Blood sample to identify relevant biomarker of the disease
Research biomarkers for diagnosis, prognosis and monitoring of disease activity

Locations

Country Name City State
France Service de rhumatologie pédiatrique Hôpital Femme-Mère-enfant Bron
France Hôpital Couple Enfant Grenoble
France Hôpital Claude Huriez (CHU de Lille) Lille
France Hôpital Jeanne de Flandre (CHU de Lille) Lille
France Hôpital Archet 2 Nice
France Hôpital Kremlin-Bicêtre (AP-HP) Paris
France Hôpital Necker-Enfants Malades (AP-HP) Paris
France Hôpital Robert Debré (AP-HP) Paris
France CLCC Henri Becquerel Rouen
France Hôpital Nord (CHU ST-Etienne) Saint-Étienne Saint Etienne

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To Identify germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood Identification of germline or somatic genetic mutations, based on high-throughput sequencing data (exome, genome or transcriptome). Baseline
Secondary Measurement of disease activity according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (Min value: 0 - Max value: 105), with higher values mean higher disease activity Baseline
Secondary Levels of anti-double stranded DNA in patients sera Baseline
Secondary Levels of complement components C3 and C4 in patients sera Baseline
Secondary Level of IFN Signature score Mesured by 6-gene Type 1 IFN Signature Score Baseline
Secondary Concentration of circulating IFN-alpha In serum using single-molecule array digital ELISA technology (Simoa) Baseline
Secondary Presence or absence of anti-type I interferons autoantibodies in patients sera Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04078698 - Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Completed NCT03266172 - A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses Phase 1
Completed NCT03649412 - A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 Phase 1
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed NCT00975936 - Phase 0 Microdose Study Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT01210716 - Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Phase 3
Completed NCT00820469 - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Phase 4
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Withdrawn NCT03239600 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) Phase 2
Completed NCT04872257 - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo N/A
Recruiting NCT06019611 - Epidural Stimulation in Multiple Sclerosis N/A
Recruiting NCT05030779 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus Early Phase 1
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04005456 - Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design N/A
Recruiting NCT05085444 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Early Phase 1
Recruiting NCT05853835 - First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 Phase 1